- Home
- PEPG vs LRMR Comparison
PEPG vs LRMR Comparison
Compare PEPG & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- LRMR
- Stock Information
- Founded
- PEPG 2018
- LRMR N/A
- Country
- PEPG United States
- LRMR United States
- Employees
- PEPG N/A
- LRMR N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- PEPG Health Care
- LRMR Health Care
- Exchange
- PEPG Nasdaq
- LRMR Nasdaq
- Market Cap
- PEPG 317.6M
- LRMR 360.3M
- IPO Year
- PEPG 2022
- LRMR N/A
- Fundamental
- Price
- PEPG $4.51
- LRMR $4.31
- Analyst Decision
- PEPG Strong Buy
- LRMR Strong Buy
- Analyst Count
- PEPG 6
- LRMR 7
- Target Price
- PEPG $9.17
- LRMR $16.71
- AVG Volume (30 Days)
- PEPG 970.7K
- LRMR 2.5M
- Earning Date
- PEPG 11-06-2025
- LRMR 11-14-2025
- Dividend Yield
- PEPG N/A
- LRMR N/A
- EPS Growth
- PEPG N/A
- LRMR N/A
- EPS
- PEPG N/A
- LRMR N/A
- Revenue
- PEPG N/A
- LRMR N/A
- Revenue This Year
- PEPG N/A
- LRMR N/A
- Revenue Next Year
- PEPG N/A
- LRMR N/A
- P/E Ratio
- PEPG N/A
- LRMR N/A
- Revenue Growth
- PEPG N/A
- LRMR N/A
- 52 Week Low
- PEPG $0.88
- LRMR $1.61
- 52 Week High
- PEPG $7.62
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- PEPG 52.66
- LRMR 51.28
- Support Level
- PEPG $4.36
- LRMR $3.87
- Resistance Level
- PEPG $5.65
- LRMR $4.46
- Average True Range (ATR)
- PEPG 0.40
- LRMR 0.30
- MACD
- PEPG -0.12
- LRMR -0.01
- Stochastic Oscillator
- PEPG 11.64
- LRMR 65.93
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.